Is capmatinib effective in treating MET mutated lung cancer? What is the patient feedback?

Capmatinib (Capmatinib) is the first targeted drug targeting MET exon 14 skipping mutations (METex14) and is mainly used for patients with advanced non-small cell lung cancer (NSCLC). Clinical data shows that capmatinib has an objective response rate (ORR) of up to 68% in untreated patients, and a response rate of 41% in treated patients, indicating that its efficacy is relatively stable. After taking it, many patients' lung lesions shrank, and symptoms such as cough and chest tightness were significantly relieved. Some patients' quality of life was greatly improved. However, the efficacy of capmatinib varies among individuals, and some patients may develop resistance after several months. Therefore, regular review is required during treatment to evaluate changes in the condition.